BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 20539080)

  • 1. Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries.
    Orsi F; d'almeida C
    Curr Opin HIV AIDS; 2010 May; 5(3):237-41. PubMed ID: 20539080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRIPS post-2005 and access to new antiretroviral treatments in southern countries: issues and challenges.
    Orsi F; D'Almeida C; Hasenclever L; Camara M; Tigre P; Coriat B
    AIDS; 2007 Oct; 21(15):1997-2003. PubMed ID: 17885289
    [No Abstract]   [Full Text] [Related]  

  • 3. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intellectual property rights, market competition and access to affordable antiretrovirals.
    Pascual F
    Antivir Ther; 2014; 19 Suppl 3():57-67. PubMed ID: 25309984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A one-time-only combination: Emergency medicine exports and the TRIPS agreement under Canada's access to medicines regime.
    Weber A; Mills L
    Health Hum Rights; 2010 Jun; 12(1):109-22. PubMed ID: 20930258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
    Halliburton M
    Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining the production costs of antiretroviral drugs.
    Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
    AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economics of effective AIDS treatment in Thailand.
    Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
    AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of intellectual property rights in treatment access: challenges and solutions.
    't Hoen E; Passarelli CA
    Curr Opin HIV AIDS; 2013 Jan; 8(1):70-4. PubMed ID: 23201855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Companies reduce prices for HIV drugs in developing countries.
    Gottlieb S
    Bull World Health Organ; 2000; 78(6):862. PubMed ID: 10916926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries.
    Waning B; Diedrichsen E; Moon S
    J Int AIDS Soc; 2010 Sep; 13():35. PubMed ID: 20840741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The economics of health care in developing countries: what the fight against the AIDS epidemics has changed].
    Moatti JP
    C R Biol; 2008 Dec; 331(12):964-72. PubMed ID: 19027697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATT and the gap: how to save lives.
    James JS
    AIDS Treat News; 1998 Nov; (No 307):1, 3-6. PubMed ID: 11366123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs associated with combination antiretroviral therapy in HIV-infected patients.
    Yazdanpanah Y
    J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.
    Renaud-Théry F; Nguimfack BD; Vitoria M; Lee E; Graaff P; Samb B; Perriëns J
    AIDS; 2007 Jul; 21 Suppl 4():S89-95. PubMed ID: 17620758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustaining treatment costs: who will pay?
    Zewdie D; De Cock K; Piot P
    AIDS; 2007 Jul; 21 Suppl 4():S1-4. PubMed ID: 17620744
    [No Abstract]   [Full Text] [Related]  

  • 18. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
    Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
    PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. World Trade Organization still threatens supply of affordable AIDS drugs.
    Hagmann M
    Bull World Health Organ; 2002; 80(9):762-3. PubMed ID: 12378300
    [No Abstract]   [Full Text] [Related]  

  • 20. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
    Cohen-Kohler JC; Forman L; Lipkus N
    Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.